Yarrow Bioscience Inc (YARW) - Total Assets
Based on the latest financial reports, Yarrow Bioscience Inc (YARW) holds total assets worth $25.87 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Yarrow Bioscience Inc generate cash for how efficiently the company converts equity into cash flow.
Yarrow Bioscience Inc - Total Assets Trend (2015–2025)
This chart illustrates how Yarrow Bioscience Inc's total assets have evolved over time, based on quarterly financial data. See Yarrow Bioscience Inc (YARW) stock price for real-time trading data and today's change.
Yarrow Bioscience Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Yarrow Bioscience Inc's total assets of $25.87 Million consist of 99.5% current assets and 0.5% non-current assets. Explore YARW working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Yarrow Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yarrow Bioscience Inc's current assets represent 99.5% of total assets in 2025, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 79.7% of total assets in 2025, down from 99.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Yarrow Bioscience Inc Competitors by Total Assets
Key competitors of Yarrow Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
USA | $1.08 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
USA | $1.21 Billion |
|
LegoChem Biosciences Inc
KQ:141080
|
Korea | ₩652.93 Billion |
Yarrow Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.86 | 4.47 | 2.23 |
| Quick Ratio | 20.86 | 4.47 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $24.55 Million | $42.62 Million | $70.81 Million |
Yarrow Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Yarrow Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.74 |
| Asset Growth Rate (YoY) | -54.9% |
| Total Assets | $30.16 Million |
| Market Capitalization | $52.62 Million USD |
Valuation Analysis
Above Book Valuation: The market values Yarrow Bioscience Inc's assets above their book value (1.74x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Yarrow Bioscience Inc's assets decreased by 54.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Yarrow Bioscience Inc (2015–2025)
The table below shows the annual total assets of Yarrow Bioscience Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $30.16 Million | -54.92% |
| 2024-12-31 | $66.91 Million | -31.51% |
| 2023-12-31 | $97.69 Million | +139.67% |
| 2022-12-31 | $40.76 Million | -39.21% |
| 2021-12-31 | $67.05 Million | -28.48% |
| 2020-12-31 | $93.74 Million | +18.41% |
| 2019-12-31 | $79.17 Million | -43.42% |
| 2018-12-31 | $139.93 Million | +109.26% |
| 2017-12-31 | $66.87 Million | +59.01% |
| 2016-12-31 | $42.05 Million | -4.17% |
| 2015-12-31 | $43.88 Million | -- |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more